Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.
Identifieur interne : 001D17 ( Ncbi/Checkpoint ); précédent : 001D16; suivant : 001D18Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.
Auteurs : David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan ; Andrew H. Evans ; Andrew J. Lees ; Anette SchragSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Adult, Aged, Chi-Square Distribution, Dopamine (metabolism), Dopamine Agonists (adverse effects), Female, Gambling, Humans, Levodopa (adverse effects), Male, Middle Aged, Odds Ratio, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Prospective Studies, Reaction Time (drug effects), Retrospective Studies, Risk Factors.
- MESH :
- chemical , adverse effects : Dopamine Agonists, Levodopa.
- chemical , metabolism : Dopamine.
- drug effects : Reaction Time.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Chi-Square Distribution, Female, Gambling, Humans, Male, Middle Aged, Odds Ratio, Prospective Studies, Retrospective Studies, Risk Factors.
Abstract
Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co-morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co-prescribed, suggesting possible cross-sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti-parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine.
DOI: 10.1002/mds.21611
PubMed: 17580327
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002622
- to stream PubMed, to step Curation: 002622
- to stream PubMed, to step Checkpoint: 002658
- to stream Ncbi, to step Merge: 001D17
- to stream Ncbi, to step Curation: 001D17
Links to Exploration step
pubmed:17580327Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.</title><author><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A" last="Gallagher">David A. Gallagher</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free & University College Medical School, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S" last="O'Sullivan">Sean S. O'Sullivan</name></author><author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H" last="Evans">Andrew H. Evans</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21611</idno><idno type="RBID">pubmed:17580327</idno><idno type="pmid">17580327</idno><idno type="wicri:Area/PubMed/Corpus">002622</idno><idno type="wicri:Area/PubMed/Curation">002622</idno><idno type="wicri:Area/PubMed/Checkpoint">002658</idno><idno type="wicri:Area/Ncbi/Merge">001D17</idno><idno type="wicri:Area/Ncbi/Curation">001D17</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D17</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.</title><author><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A" last="Gallagher">David A. Gallagher</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free & University College Medical School, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S" last="O'Sullivan">Sean S. O'Sullivan</name></author><author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H" last="Evans">Andrew H. Evans</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chi-Square Distribution</term><term>Dopamine (metabolism)</term><term>Dopamine Agonists (adverse effects)</term><term>Female</term><term>Gambling</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Prospective Studies</term><term>Reaction Time (drug effects)</term><term>Retrospective Studies</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Reaction Time</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chi-Square Distribution</term><term>Female</term><term>Gambling</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Prospective Studies</term><term>Retrospective Studies</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co-morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co-prescribed, suggesting possible cross-sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti-parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H" last="Evans">Andrew H. Evans</name><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S" last="O'Sullivan">Sean S. O'Sullivan</name><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A" last="Gallagher">David A. Gallagher</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001D17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:17580327
|texte= Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:17580327" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |